Industry news

Pharma's digital desires thwarted by clunky organizations, lack of skilled employees

Beth Snyder Bulik / FiercePharmaMarketing

While pharma lags in some areas of digital adoption, it's generally not for lack of ambition. It's what market researcher eConsultancy called healthcare companies' "fits and starts" in their embrace of digital technology, in a recent study done with Ogilvy CommonHealth and OgilvyRED.

Precision medicine in the real world

Mari Serebrov / BioWorld

In a perfect world, doctors would have the diagnostics to determine the right treatment for each patient at the right dose and the right time. It would be called precision medicine.

British docs weigh in on pharma, and it's no better than most U.S. opinions

Beth Snyder Bulik / FiercePharmaMarketing

Pharma is snookered in England too. British healthcare providers (HCPs) are just as unhappy with drugmakers as everyone else. The newest survey finds that more than 40% of U.K. doctors view the industry negatively, reports healthcare data intelligence firm Binley's.

12 October 2015

Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space (SCS™) Drug Administration

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced completion of enrollment in the company’s Phase 2 clinical trial (Dogwood) of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using SCS™ drug administration for the treatment of macular edema associated with non-infectious uveitis. Clearside remains on track to report top-line Phase 2 CLS-TA data by the end of 2015.

New report explores the liver diseases therapeutics market that is poised to grow at 15% CAGR to 2019

WhaTech

Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment.

Oncologists' pricing pushback mounts as docs snub costly me-too drugs

Carly Helfand / FiercePharma

Major oncology groups, including the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), are working on tools to help size up the value that pricey new treatments provide. But in the meantime, some doctors are taking matters into their own hands.

Big Pharma teams up to defeat drug pricing proposal in California

Emily Wasserman / FiercePharma

California wants to cap drug prices, but Big Pharma isn't having it. Amid a growing backlash over drug pricing, companies such as Johnson & Johnson ($JNJ) and Bristol-Myers Squibb ($BMY) are funneling millions of dollars into stamping out a new proposal that would curb drug spending in the state.

The data difference? Publicis adds data practice to sharpen healthcare media buying and planning

Beth Snyder Bulik / FiercePharmaMarketing

Publicis Health Media is marrying healthcare data to traditional media metrics for a digital mix that could cut pharma marketing costs and potentially improve patient care at the same time.

The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews

Damian Garde / Fierce Biotech

Big Pharma has been willing to pay hundreds of millions of dollars for a shortcut to FDA approval, buying up priority review vouchers created to incentivize new drugs for neglected diseases. But the agency seems less than enthusiastic about honoring its end of the bargain, with one top official expressing concerns about how the voucher program might harm the FDA's core mission.

Biotech IPOs Slow to Trickle as Stock Rout Rattles Investors

Alex Barinka, Caroline Chen / Bloomberg Business

The biotechnology sector’s two-and-a-half-year deluge of public market debuts, with dozens of companies raising billions of dollars in funding, is now down to a trickle.